A Phase 2 interventional study of Camrelizumab and Paclitaxel in Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms and Oral Cavity Neoplasm, sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia. Not yet recruiting at 1 site in Russia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 8 under way, 2 of them phase 3. camrelizumab · Squamous Cell Carcinoma of Head and Neck.
Among the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 11 in phase 2, and was the 11th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →8 of the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–65
Xuekui Liu
Ages 18–70
Yue He, MD
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 46 across the 13 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
National Medical Research Radiological Centre of the Ministry of Health of Russia is the lead sponsor of 11 studies on the registry; 6 are open to participants now.
National Medical Research Radiological Centre of the Ministry of Health of Russia has 1 study filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA) squamous cell carcinoma of the oral cavity and/or larynx.
Fifty patients will receive 3 cycles of therapy (camrelizumab 200 mg IV, paclitaxel 175 mg/m2 IV, carboplatin AUC6 IV, Day 1 every 21 days) followed by radical surgery 4-6 weeks later. Patients are then stratified to risk-adapted adjuvant therapy based on pathological findings (radiation or chemoradiation with cisplatin if adverse features present).
The primary endpoint is the pathological complete response (pCR) rate and major pathological response (MPR, \<10% viable tumor cells) rate at surgery. Secondary endpoints include objective response rate (ORR) by imaging (MRI/PET-CT), correlation of PET-CT metabolic response with pathological response, proportion requiring adjuvant chemoradiation, and 3-year event-free survival compared to historical controls.
Study period: 2026-2029.
Investigator-initiated, single-arm, phase II study conducted at P.A. Hertsen Moscow Oncology Research Institute. Protocol approved by Local Ethics Committee (#1187/132).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive 3 cycles of camrelizumab + paclitaxel + carboplatin followed by surgery. Number of Participants: 50 (Anticipated)
Drug: Camrelizumab · Drug: Paclitaxel · Drug: carboplatin · Procedure: Radical Surgery
200 mg IV on Day 1, every 21 days for 3 cycles
Also known as: SHR-1210
175 mg/m² IV on Day 1, every 21 days for 3 cycles
Also known as: Taxol
AUC 6 IV on Day 1, every 21 days for 3 cycles
Also known as: Paraplatin
Standard radical resection 4-6 weeks after neoadjuvant therapy
Pathological Complete Response (pCR) Rate
Rate of complete pathological response (absence of viable tumor cells in resected specimen)
Time frame: At the time of surgery (approximately 10-12 weeks from baseline)
Major Pathological Response (MPR) Rate
Rate of major pathological response (\<10% viable tumor cells in resected specimen)
Time frame: At the time of surgery (approximately 10-12 weeks from baseline)
Objective Response Rate (ORR)
Rate of objective response by imaging (MRI/PET-CT) compared to historical TPF control
Time frame: After 3 cycles of neoadjuvant therapy (approximately 9 weeks)
3-Year Event-Free Survival (EFS)
EFS compared to historical control (surgery + RT/CRT)
Time frame: 3 years from enrollment
Incidence of Adverse Events
Safety profile compared to standard TPF induction chemotherapy
Time frame: From first dose until 30 days after surgery
Proportion Requiring Adjuvant Chemoradiation
Patients needing post-op CRT due to adverse pathological features vs historical control
Time frame: At the time of surgery
Plan to share: No — This is an investigator-initiated, single-center study conducted in Russia. Individual participant data will not be shared due to patient confidentiality requirements and institutional data protection policies.
Start is estimated for Feb 2026; primary completion for Feb 2029, 36 months later.
Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 36 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Camrelizumab · Paclitaxel · Carboplatin
Squamous Cell Carcinoma of Head and Neck →
National Medical Research Radiological Centre of the Ministry of Health of Russia